Figure 2. CD99 is required for HSC... | American Society of Hematology

$CD99 is required for HSC self-renewal. (A) Schematic of primary transplants of purified HSCs. (B) Total donor-derived PB chimerism in primary recipients (n = 6 donors and 6 recipients per genotype). (C-D) Donor-derived B-cell, T-cell, (C) and myeloid cell chimerism (D) in primary recipients). (E) BM cellularity per 2 femurs and 2 tibias. (F) Frequency and absolute number of donor-derived HSCs in the BM of primary recipients after 24 weeks. (G) Absolute number of donor-derived CMPs, GMPs, and MEPs in the BM of primary recipients. (H) Schematic of secondary transplants of unfractionated BM from primary recipients of purified HSCs and total donor-derived PB chimerism in secondary recipients (n = 6 donors and 6 recipients per genotype). (I) Schematic of primary and secondary transplants of unfractionated BM. Total donor-derived PB chimerism in primary recipients (n = 6 donors and n = 10 recipients per genotype) and secondary recipients (n = 6 donors and n = 10 recipients per genotype). (J) Schematic of primary and secondary competitive transplants of unfractionated BM. Total donor-derived PB chimerism in primary recipients (n = 6 donors and n = 10 recipients per genotype). (K) Number of secondary recipients with multilineage engraftment (defined as >0.5% donor myeloid and lymphoid cells) at 16 weeks after transplant. Statistical significance was assessed using 2-tailed Student t tests for panels A-J and Fisher exact test for panel K (∗P < .05; ∗∗P < .01; ∗∗∗P < .005; +P < .0005). P values for selected nonsignificant trends are also shown; data are represented as mean ± standard error in panels A-D,H-J and mean ± standard deviation in panels E-G.$

Figure 2.

CD99 is required for HSC self-renewal. (A) Schematic of primary transplants of purified HSCs. (B) Total donor-derived PB chimerism in primary recipients (n = 6 donors and 6 recipients per genotype). (C-D) Donor-derived B-cell, T-cell, (C) and myeloid cell chimerism (D) in primary recipients). (E) BM cellularity per 2 femurs and 2 tibias. (F) Frequency and absolute number of donor-derived HSCs in the BM of primary recipients after 24 weeks. (G) Absolute number of donor-derived CMPs, GMPs, and MEPs in the BM of primary recipients. (H) Schematic of secondary transplants of unfractionated BM from primary recipients of purified HSCs and total donor-derived PB chimerism in secondary recipients (n = 6 donors and 6 recipients per genotype). (I) Schematic of primary and secondary transplants of unfractionated BM. Total donor-derived PB chimerism in primary recipients (n = 6 donors and n = 10 recipients per genotype) and secondary recipients (n = 6 donors and n = 10 recipients per genotype). (J) Schematic of primary and secondary competitive transplants of unfractionated BM. Total donor-derived PB chimerism in primary recipients (n = 6 donors and n = 10 recipients per genotype). (K) Number of secondary recipients with multilineage engraftment (defined as >0.5% donor myeloid and lymphoid cells) at 16 weeks after transplant. Statistical significance was assessed using 2-tailed Student t tests for panels A-J and Fisher exact test for panel K (∗P < .05; ∗∗P < .01; ∗∗∗P < .005; +P < .0005). P values for selected nonsignificant trends are also shown; data are represented as mean ± standard error in panels A-D,H-J and mean ± standard deviation in panels E-G.

This Feature Is Available To Subscribers Only